The CH3 homodimer at the C-terminal end of the antibody heavy chain is the key noncovalent interaction stabilizing antibody proteins. Here, we use single-molecule force spectroscopy to investigate the dissociation mechanics of CH3 as a proxy for antibody mechanical stability. We find the CH3 homodimer to be a highly stable complex, and its dissociation force of >150 pN at a loading rate of ≈5500 pN/s exceeds the stability of most protein-protein interactions studied to date. Separated CH3 monomers, on the other hand, are mechanically labile and only short-lived. Each CH3 monomer contains a conserved buried disulfide bridge, and we find that the successive reduction of one or both disulfide bridges in the dimer results in a stepwise decrease of the dissociation force. This suggests a structural role of the disulfide bridges helping to mold the high-affinity domain-domain interface, even though they are neither required for nor directly involved in dimerization. Taken together, our results set a limit on how much force a single antibody can bear and reveal the CH3 homodimer as a mechanical fastener that prevents antibody dissociation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/ja405076j | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A novel SARS-CoV-2 Beta RBD DNA vaccine directly targeted to antigen-presenting cells induces strong humoral and T cell responses.
Sci Rep
November 2023
Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway.
Throughout the COVID-19 pandemic, several variants of concern (VoC) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have evolved, affecting the efficacy of the approved COVID-19 vaccines. To address the need for vaccines that induce strong and persistent cross-reactive neutralizing antibodies and T cell responses, we developed a prophylactic SARS-CoV-2 vaccine candidate based on our easily and rapidly adaptable plasmid DNA vaccine platform. The vaccine candidate, referred to here as VB2129, encodes a protein homodimer consisting of the receptor binding domain (RBD) from lineage B.
View Article and Find Full Text PDFProtein A and CaptureSelect FcXP Affinity Resins Possess the Capability of Differentiating Hole-hole Homodimer Isoforms.
Protein Pept Lett
July 2023
Technology and Process Development (TPD), WuXi Biologics, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, 200131, China.
Background: Knobs-into-holes (KiH) technology has been widely used in asymmetric bispecific antibody (bsAb) construction to promote heavy chain heterodimerization. However, despite the great improvement of heterodimer formation by this strategy, homodimers (especially the holehole homodimer) can still be generated at low levels. Consequently, hole-hole homodimer is a common byproduct associated with the production of KiH bsAbs.
View Article and Find Full Text PDFComparing Antibody Interfaces to Inform Rational Design of New Antibody Formats.
Front Mol Biosci
January 2022
Department of General, Inorganic and Theoretical Chemistry, Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck, Austria.
As the current biotherapeutic market is dominated by antibodies, the design of different antibody formats, like bispecific antibodies and other new formats, represent a key component in advancing antibody therapy. When designing new formats, a targeted modulation of pairing preferences is key. Several existing approaches are successful, but expanding the repertoire of design possibilities would be desirable.
View Article and Find Full Text PDFCharacterization and Monitoring of a Novel Light-heavy-light Chain Mispair in a Therapeutic Bispecific Antibody.
J Pharm Sci
August 2021
Analytical Sciences, Biopharmaceutical Development, Biopharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD 20878, United States. Electronic address:
Article Synopsis
- The text discusses the use of site-specific cysteine engineering and genetic mutations in creating bispecific antibodies (bsAb), focusing on a novel mispair called LHL where disulfide bonds form between engineered cysteines in a specific antibody construct.
- The study outlines various physicochemical assays, like hydrophobic interaction chromatography and mass spectrometry, used to monitor and control this mispairing impurity during the manufacturing process to ensure bioactivity.
- Results indicated that the LHL species was reduced from 1.3 - 1.9% to as low as 0.2% in the final product through enhanced chromatography techniques, showcasing the effectiveness of the analytical methodologies for future bsAb constructs.
A single mutation increases heavy-chain heterodimer assembly of bispecific antibodies by inducing structural disorder in one homodimer species.
J Biol Chem
July 2020
Department of Antibody Engineering, Ichnos Sciences S.A., Biopôle Lausanne-Epalinges, Epalinges, Switzerland
We previously reported efficient heavy-chain assembly of heterodimeric bispecific antibodies by exchanging the interdomain protein interface of the human IgG1 CH3 dimer with the protein interface of the constant α and β domains of the human T-cell receptor, a technology known as bispecific engagement by antibodies based on the T-cell receptor (BEAT). Efficient heterodimerization in mammalian cell transient transfections was observed, but levels were influenced by the nature of the binding arms, particularly in the Fab-scFv-Fc format. In this study, we report a single amino acid change that significantly and consistently improved the heterodimerization rate of this format (≥95%) by inducing partial disorder in one homodimer species without affecting the heterodimer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!